Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management

详细信息    查看全文

• 作者：S.J.E. Hwang^a ; ^b ; ^{shelley.hwang@hotmail.com} ; R. Anforth^a ; ^b ; G. Carlos^a ; ^b ; P. Fernandez-Peñ ; as^a ; ^b
• 关键词：B-Raf inhibitors ; Mitogen-activated protein kinase inhibitor ; Anti-Cytotoxic T-lymphocyte-associated protein 4 ; Anti-Programmed cell death-1 ; Metastatic melanoma ; Cutaneous adverse event
• 刊名：Actas Dermo-Sifiliográficas
• 出版年：2017
• 出版时间：January-February 2017
• 年：2017
• 卷：108
• 期：1
• 页码：6-16
• 全文大小：2596 K
• 卷排序：108

文摘

Over the past decade, targeted therapies such as BRAF inhibitors, MEK inhibitors and immunotherapies such as anti-CTLA4 and anti-PD1 antibodies have emerged as novel treatments of advanced melanoma. Along with increased use of these therapies, a range of cutaneous adverse events have also emerged, varying from more serious and frequent cutaneous squamous cell carcinoma to mere cosmetic changes such as curly hair or rare severe toxic epidermal necrolysis. Early detection and management of these cutaneous adverse events will aid patients to receive accurate treatment, avoid unnecessary discontinuation of anti-tumour treatment and improve the patient's overall quality of life. This review will describe various cutaneous adverse events of anti-melanoma therapies and its management.